Sanofi under fire over priority US access to COVID-19 vaccine

Sanofi is facing criticism after CEO Paul Hudson said the US was likely to have priority access on any COVID-19 vaccine produced by the French pharmaceutical company.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

MSD buys Themis as part of COVID-19 plans

28 May 2020 Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

Americas

Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal

3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

MSD buys Themis as part of COVID-19 plans

28 May 2020 Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

Americas

Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal

3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

MSD buys Themis as part of COVID-19 plans

28 May 2020 Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

Americas

Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal

3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

Sanofi under fire over priority US access to COVID-19 vaccine

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features